Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 201 - 250 out of 103,491

Document Document Title
WO/2014/195848A1
Disclosed are an alpha 7 nAChR receptor modulator compound, 4- (5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)- 1,4-dimethyl- lH-pyrrol-3- yljbenzenesulfonamide, its tautomeric form, its pharmaceutically acceptable salts, pharmaceutical comp...  
WO/2014/197775A1
A compound useful as a Sirt2 or Sirt5 inhibitor having the formula (1) wherein: R1 is a hydrocarbon group having at least two carbon atoms connected by carbon-carbon bonds, wherein said hydrocarbon group is optionally endcapped by a neut...  
WO/2014/195593A2
The invention relates to compounds of formula (I) as well as to neurogenic enantiomers thereof, acid salts thereof, hydrates thereof or to solvation products thereof. Among a large number of possible meanings, X is a halogen, Y is an oxy...  
WO/2014/195553A1
The invention relates to a compound of formula (I), where R is selected from a methyl group or an ethyl group (I), the hydroxy acid forms of said compound, the pharmaceutically acceptable salts of said hydroxy acids, and pharmaceutically...  
WO/2014/194975A1
The compound N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-5-eth yl-1-(pyrimidin-5-yl)-1 H-pyrazole-4-carboxamide and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, ...  
WO/2014/196658A1
Provided is a therapeutic drug for neuromyelitis optica. Specifically provided is an antibody or a functional fragment thereof that specifically binds to the extracellular domain of aquaporin-4, and includes: a heavy chain variable regio...  
WO/2014/195322A1
The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, to processes for making these compounds, and t...  
WO/2014/197744A1
Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations optionally in combination with at least one other medication, and to combination products...  
WO/2014/195352A1
The invention relates to transdermal therapeutic system for the transdermal administration of buprenorphine, comprising a buprenorphine-containing self-adhesive layer structure comprising A) a buprenorphine-impermeable backing layer, and...  
WO/2014/196644A1
The inventors perfected the present invention as a result of a study into IK1 channel activators and a confirmation that a benzothiophene compound exhibits efficacy against visceral pain, inflammatory pain, osteoarthritic pain, neuropath...  
WO/2014/194991A1
A pharmaceutical formulation, comprising agomelatine in the form of agomelatine co-crystal with a co-crystal former selected from the group of organic acids in an amount corresponding to 15 - 22 mg agomelatine dose per one dosage unit an...  
WO/2014/195321A1
The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, to processes for making these compounds, and t...  
WO/2014/195323A1
The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, to processes for making these compounds, and t...  
WO/2014/190440A9
The present invention relates to an immediate release orally administrable abuse-deterrent pharmaceutical formulation comprising: at least one pharmaceutically active ingredient susceptible to abuse; at least one gelling polymeric compou...  
WO/2014/193060A1
The present invention relates to the concomitant administration of a human bone marrow-derived mesenchymal stem cell (hBM-MSC) and minocycline, and alleviates the clinical severity of multiple sclerosis compared to a conventional separat...  
WO/2014/190440A1
The present invention relates to an immediate release orally administrable abuse-deterrent pharmaceutical formulation comprising: at least one pharmaceutically active ingredient susceptible to abuse; at least one gelling polymeric compou...  
WO/2014/190936A1
Disclosed is use of an active ingredient in the preparation of a medicament, wherein the medicament is used to increase the expression quantity of SIRT1 mRNA and/or reduce the expression quantity of SOCS3 mRNA, and it can especially it c...  
WO/2014/193190A1
The present invention relates to a percutaneously absorbable preparation containing rotigotine and, more specifically, provides a percutaneously absorbable preparation and a method for preparing same, the percutaneously absorbable prepar...  
WO/2014/194166A1
The invention provides methods of treating, inhibiting, or ameliorating a disease characterized by aberrant deposition of beta amyloid in a subject in need thereof, comprising administering to a subject a therapeutic amount of an interle...  
WO/2014/191632A1
The present invention relates to arylthiazine compounds, metabolites, N-oxides, amides, esters,pharmaceutically acceptable salts, hydrates and solvates thereof and their use as cytoprotectants in the treatment or prophylaxis of diseases ...  
WO/2014/193935A1
The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof, wherein ...  
WO/2014/190398A1
An inhibitor of amyloid fibril formation comprising: (a) a backbone that is hydrophobic or hydrophilic and comprises from 1 to about 1000 repeating units; (b) one or more hydrophobic or hydrophilic pendant chains linked to the backbone, ...  
WO/2014/192865A1
The present invention relates to a therapeutic agent for neurodegenerative diseases and mental diseases, which comprises, as an active ingredient, a compound represented by formula (1) [wherein Z1 represents a halogen atom, an alkyl grou...  
WO/2014/191547A1
The present invention concerns a compound having the following formula (I) for its use as drug in the treatment and/or the prevention of depressions, with the proviso that said compound is not for use as drug in the treatment of women de...  
WO/2014/192868A1
The present invention provides cyclic aminomethyl pyrimidine derivatives and pharmaceutically permissible salts thereof that exhibit high selectivity for dopamine D4 receptors and are useful as therapeutic agents for attention deficit hy...  
WO/2014/191992A1
This invention provides a method of enhancing NMDAR-mediated neurotransmission in a disease associated with NMDAR antibody production, said method comprising administering an NMDAR agonist, an alanine-serine-cysteine transporter inhibito...  
WO/2014/193781A1
The invention provides certain 3,4-dihydroisoquinolin-2(1H)-yl compounds, particularly compounds of formula (I), and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula (I) to treat ...  
WO/2014/192698A1
A therapeutic agent for pain that is characterized by comprising 1-[3-(9H-carbazol-9-yl)propyl]-4-(2-methoxyphenyl)-4-piperid inol or a pharmaceutically acceptable salt thereof. Thus, provided is a therapeutic agent for pain that is capa...  
WO/2014/191396A1
The invention relates to a pharmaceutical dosage form comprising: (i) at least one formed segment (S1), which contains a first pharmacologically active ingredient (A1) and provides prolonged release thereof, and (ii) at least one further...  
WO/2014/190763A1
Provided are polyethylene glycol drug conjugates of general formula (I), (II) or (III) and pharmaceutical compositions and a use thereof. The conjugates are formed by combining low molecular weight polyethylene glycol with 2-4 drug molec...  
WO/2014/190758A1
Disclosed are an oxo indirubin or isoindigo derivative, an oxo aza indirubin or isoindigo derivative, and their optical isomers, racemes, cis/trans isomers and pharmaceutically acceptable salts, which can be used for preparing a drug for...  
WO/2014/192022A1
The present invention provides pharmaceutical compositions of rasagiline, its enantiomer or salts thereof. In particular, the invention relates to stabilizer free pharmaceutical compositions of rasagiline, its enantiomer or salts thereof...  
WO/2014/187945A1
Compositions for prevention or treatment of non-inflammatory neuronal damage from brain trauma and strokes are provided, and the compositions contain a therapeutically effective amount of a compound selected from the group consisting of ...  
WO/2014/187654A1
The present invention is referred to novel polymeric conjugates to which at least it is linked a fibril disruptor agent and/or a aggregates blocking agent, and additionally a targeting moiety and/or a probe for therapy and diagnosis. In ...  
WO/2014/189071A1
 Provided are stem cells for transplantation composed of MSCs capable of overexpression of IL-10 as means for providing: MSCs for transplantation having improved take ratio and cell survivability after transplantation, and having high ...  
WO/2014/187225A1
Disclosed are a use of mefloquine in the preparation of a medication for preventing neuropathic pain and a pharmaceutical composition comprising a prophylactically effective amount of mefloquine and a pharmaceutical acceptable carrier.  
WO/2014/188193A1
The present invention relates to compounds of the formula (I): as inhibitors of peptidylarginine deiminases (PADs). It also concerns their use in therapy, particularly in the prophylaxis or treatment of neural injury, and other condition...  
WO/2014/187946A1
Compositions for treatment or prevention of autism disorders are provided, and the compositions contain a therapeutically effective amount of a compound selected from the group consisting of Menthol, Linalool, Icilin and combinations the...  
WO/2014/190270A1
The present application relates to analogues of morphan and morphinan, compositions thereof, and methods for treating a disease or condition comprising administering an effective amount of the compounds or compositions to a subject in ne...  
WO/2014/188980A1
The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1), a pharmaceutically acceptable salt of this compound or a solvate of this compound. The present invention also provides: thi...  
WO/2014/188046A1
The invention relates to neuroprotective, antioxidant steroidal nitrones to which the blood-brain barrier is highly permeable, as potential drugs for the treatment of a cerebral stroke or ischaemia, Alzheimer and Parkinson disease and am...  
WO/2014/187365A1
The present invention relates to a oxabicyclo derivative, preparation method and use thereof, specifically to oxabicyclo derivatives shown by general formula (I) or hydrates, solvates, stereoisomers thereof, pharmaceutically acceptable s...  
WO/2014/187922A1
Provided is a SLC2A class I transporter inhibitor compound for use in medicine, which compound comprises the following formula (I): wherein A and Z may be the same or different and are each independently selected from C, N, O and S; each...  
WO/2014/190030A1
Alzheimer's disease is treated by attacking hyperactive microglia preferably before excessive beta amyloid is built up by administering tin-117m-DOTA annexin V. This compound in low radioactive doses selectively binds to the aged hyperac...  
WO/2014/190150A1
Methods for the efficient isolation and use of pluripotent adipose-derived stem cells (PASCs) are provided. In certain embodiments the methods involve providing an adipose tissue sample from which the stromal vascular fraction is co-cult...  
WO/2014/190313A3
The application relates to Dynorphin A analog compounds and uses thereof for treating pain in humans and lower animals; the compounds interact with the bradykinin receptor to relieve pain. The preferred compounds are [des-Arg7]-dynorphin...  
WO/2014/187942A1
Compositions for treatment or prevention of neurodegenerative disorders are provided, and the compositions contain a therapeutically effective amount of a compound selected from the group consisting of Menthol, Linalool, Icilin and combi...  
WO/2014/187943A1
Compositions for treatment or prevention of depression are provided, and the compositions contain a therapeutically effective amount of a compound selected from the group consisting of Menthol, Icilin and combinations thereof. Methods fo...  
WO/2014/189947A1
The present disclosure is generally directed to compositions and methods for treating apicomplexan protozoan related disease, such as toxoplasmosis and cryptosporidiosis.  
WO/2014/186824A1
Methods and implants for treating neurological, muscular and other cells having an electrical potential, with an infusion of antagonists or inverse agonists (such as flumazenil for the benzodiazepine receptor, or naltrexone for the opiat...  

Matches 201 - 250 out of 103,491